Pharmaceuticals, Biotechnology and Life Sciences
Neovacs has completed patient enrollment for for its phase IIb clinical study, IFN-K-002, evaluating IFNalpha Kinoid for the treatment of lupus.
Takeda and TiGenix reported on Tuesday that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for review the file on investigational compound Cx601 to treat complex perianal fistulas in patients with Crohn’s disease.
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.
Health Canada has issued a Notice of Compliance (NOC) for Horizon Pharma’s Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children 2 years of age and older.
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.
Ceylad said on Monday that it’s gotten promising early clinical results at the 3-month follow-up of the first dose-level in the solid tumor arm of the THINK trial (THerapeutic Immunotherapy with CAR-T NKR-2).
The clinical trials and research outsourcing (CRO) market is growing, leveraging the global pharmaceutical industry’s urgent need to succeed in late clinical trials and build the pipeline of new molecules, a growth partnership company that analyses the market Frost & Sullivan said.
LEO Pharma has dosed patients in a phase 3 clinical study of its investigational human monoclonal antibody tralokinumab.
CTI BioPharma has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for Trisenox (arsenic trioxide).
Bristol-Myers Squibb on Wednesday said it would present 23 abstracts related to Orencia (abatacept), including new data on the role of biomarkers and MRI in RA patient identification and treatment, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, Spain.